title: Human papillomavirus testing in cervical cancer screening.
abstract: Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.
authors.affiliation: Global Cancer Initiative, 100 Radcliffe, Dr Chestertown, MD 21620, USA. castle.philip@gmail.com
authors.forename: Philip E
authors.initials: PE
authors.lastname: Castle
authors.forename: Miriam
authors.initials: M
authors.lastname: Cremer
mesh_terms: D000328:Adult; D003127:Colposcopy; D005260:Female; D005838:Genotype; D061809:Human Papillomavirus DNA Tests; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000639:trends; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics; D030361:Papillomavirus Infections / Q000175:diagnosis* / Q000517:prevention & control; D053918:Papillomavirus Vaccines; D017410:Practice Guidelines as Topic; D014481:United States; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000821:virology*; D014626:Vaginal Smears; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines